A clinical perspective on plasma cell leukemia; current status and future directions
Abstract Primary plasma cell leukemia (pPCL) is an aggressive plasma cell disorder with a guarded prognosis. The diagnosis is confirmed when peripheral blood plasma cells (PCs) exceed 20% of white blood cells or 2000/μL. Emerging data demonstrates that patients with lower levels of circulating (PCs)...
Main Authors: | Sherilyn A. Tuazon, Leona A. Holmberg, Omar Nadeem, Paul G. Richardson |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2021-02-01
|
Series: | Blood Cancer Journal |
Online Access: | https://doi.org/10.1038/s41408-021-00414-6 |
Similar Items
-
Third-line therapy for chronic myeloid leukemia: current status and future directions
by: Jorge Cortes, et al.
Published: (2021-03-01) -
Convalescent Plasma Therapy for COVID-19: Current Status and Future Directions
by: Jayanth Seshan, et al.
Published: (2020-09-01) -
The Role of Bruton’s Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions
by: Tadeusz Robak, et al.
Published: (2022-02-01) -
Acute myeloid leukemia: current progress and future directions
by: Hagop Kantarjian, et al.
Published: (2021-02-01) -
Bevacizumab--current status and future directions.
by: Midgley, R, et al.
Published: (2005)